HuR as Therapeutic Target in Cancer: What the Future Holds.

Autor:	Goutas D; First Department of Pathology, The National and Kapodistrian University of Athens, Medical School, Athens,Greece., Pergaris A; First Department of Pathology, The National and Kapodistrian University of Athens, Medical School, Athens,Greece., Giaginis C; Department of Food Science and Nutrition, University of the Aegean, Lemnos,Greece., Theocharis S; First Department of Pathology, The National and Kapodistrian University of Athens, Medical School, Athens,Greece.
Jazyk:	angličtina
Zdroj:	Current medicinal chemistry [Curr Med Chem] 2022; Vol. 29 (1), pp. 56-65.
DOI:	10.2174/0929867328666210628143430
Abstrakt:	ELAV-like protein 1 or HuR (human antigen R) is an RNA-binding protein that in humans is encoded by the ELAVL1 gene, and one of its best functions is to stabilize mRNAs in order to regulate gene expression. HuR protein overexpression has undoubtedly been linked to an increased risk of tumor growth, progression and metastasis, rendering it a potential therapeutic target candidate in cancer. Novel agents, interfering with HuR expression, have been tested, both in vitro and in vivo, with promising results. The aim of this paper is to review the existing literature regarding the potential agents that could actively act on and inhibit HuR expression. HuR molecule controls the expression of various proto-oncogenes, cytokines and growth factors, representing a major player in tumor progression, invasion and metastasis and constituting an emerging target for cancer therapy. PubMed database was thoroughly searched, and all published articles providing scientific data on molecules that can exhibit antitumorigenic effects via HuR inhibition were included. According to these data, HuR inhibition should be a promising target in cancer therapeutics. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu